New System Takes Legwork Out of Tracing Fake Drugs (China)
This article was originally published in PharmAsia News
The Shanghai FDA will increase its scrutiny of the circulation of pharmaceutical drugs as the second phase of its trading supervision system gets underway. The system supervises drugs and vaccines purchased by the city's disease control center, hospitals, and general drug stores. The Shanghai FDA will trace the entire batch of medicine immediately if any accidents occur involving adverse drug reactions or counterfeit medicines. All 128 drug wholesale companies in Shanghai must report each purchase and sale, including product details such as where it was purchased and whom it was sold to. The supervision system was launched earlier this year, when the Shanghai FDA successfully traced the origin of an immunoglobulin injection produced by the Baiyi Pharmaceutical Company from Guangdong Province within just 10 minutes after receiving notification about a safety problem. (Click here for more - May Require Free Registration
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.